The Central Illinois Community Clinical Oncology Program is a consortium of two major components, Memorial Medical Center (MMC) in Springfield and Decatur Memorial Hospital (DMH) in Decatur. They are part of a rapidly developing network of cancer resources in Central Illinois. There are 1,981 new cancer cases which will be seen by the component hospitals. The CICCOP has been functioning for many months and is led by a Principal Investigator who previously directed the Southwest Washington CCOP and sat on the governing board of SWOG. Research base affiliations are with SWOG, MDAH, NSABP and ICC. Full program elements and procedures are in place and the Operations Office and data management components are unusually well organized with centralized support, traveling data managers, and/or site clinical coordinators and nurse oncologists in each oncology unit at component hospitals and affiliated practices. A vigorous group of investigators in medical, surgical and radiation therapy oncology currently accrue patients at an annual rate of 136/year as well as provide linkage to investigators in pathology, otolaryngology, dermatology, primary care, internal medicine, gastroenterology and other specialties. Unusual expertise in studies of interstitial transplantation is offered by Dr. McGee, a world recognized senior investigator. Over the past five years this group of nine highly active investigators have accrued an average of 163 patients annually and a total of 35 patients in the past 3 months to NCI approved protocols. CICCOP projects 142.8 accrual credits for treatment protocols and 77.95 accrual credits for cancer control during the first year of NCI funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA045807-01
Application #
3558701
Study Section
(SRC)
Project Start
1987-08-15
Project End
1990-05-31
Budget Start
1987-08-15
Budget End
1988-05-31
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Voluntary Hospitals of America-Illinois
Department
Type
DUNS #
City
Springfield
State
IL
Country
United States
Zip Code
62702
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 59 publications